01687nas a2200397   4500000000100000008004100001260001300042653001500055653002300070653001600093653002100109653001100130653001000141653001200151653002500163653001900188653001500207653001600222653002600238100001500264700001700279700001600296700001500312700001400327700001300341700001500354700001500369700001400384700001700398245006900415856004100484300000900525490000700534520073400541022001401275       1989                            d  c1989 Mar10aAdolescent10aBacterial Vaccines10aBCG Vaccine10aChild, Preschool10aHumans10aIndia10aleprosy10aMycobacterium leprae10aPilot Projects10aSkin Tests10aVaccination10aVaccines, Inactivated1 aGanapati R1 aRevankar C R1 aLockwood DN1 aWilson R C1 aPrice J E1 aAshton P1 aAshton L A1 aHolmes R M1 aBennett C1 aStanford J L00aA pilot study of three potential vaccines for leprosy in Bombay.  uhttp://ila.ilsl.br/pdfs/v57n1a05.pdf  a33-70 v573 a<p>Three vaccines, BCG Glaxo alone (vaccine A), BCG Glaxo plus 10(7) killed Mycobacterium vaccae (vaccine B), and BCG Glaxo plus 10(7) killed M. leprae (vaccine C), were given to groups of selected children. The effects of these vaccines on subsequent quadruple skin testing 1-3 years after vaccination were compared. All three vaccines equally and significantly (p less than 0.00001) increased positivity to tuberculin, but only vaccine B was found to significantly enhance development of skin-test positivity to leprosin A (p less than 0.002). The data support the evidence previously obtained in rural Iran that the combination of BCG with killed M. vaccae is likely to be a better vaccine for leprosy than is BCG alone.</p>
  a0148-916X